Biomaterial Database

Relative bioavailability of Sandimmune and Sandimmune Neoral in pediatric liver recipients. 1994

R A Superina, and D K Strong, and L A Acal, and E DeLuca

Liver Transplant Program, Hospital for Sick Children, Toronto, Ontario, Canada.

UI	MeSH Term	Description	Entries
D007262	Infusions, Intravenous	The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it.	Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008657	Metabolic Clearance Rate	Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site.	Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D002648	Child	A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL.	Children
D002675	Child, Preschool	A child between the ages of 2 and 5.	Children, Preschool,Preschool Child,Preschool Children
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284	Administration, Oral	The giving of drugs, chemicals, or other substances by mouth.	Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000293	Adolescent	A person 13 to 18 years of age.	Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D001682	Biological Availability	The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action.	Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities
D016031	Liver Transplantation	The transference of a part of or an entire liver from one human or animal to another.	Grafting, Liver,Hepatic Transplantation,Liver Transplant,Transplantation, Hepatic,Transplantation, Liver,Hepatic Transplantations,Liver Grafting,Liver Transplantations,Liver Transplants,Transplant, Liver
D016572	Cyclosporine	A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).	Cyclosporin A,Ciclosporin,CsA-Neoral,CyA-NOF,Cyclosporin,Cyclosporine A,Neoral,OL 27-400,Sandimmun,Sandimmun Neoral,Sandimmune,CsA Neoral,CsANeoral,CyA NOF,OL 27 400,OL 27400

Related Publications

R A Superina, and D K Strong, and L A Acal, and E DeLuca

Conversion from Sandimmune to Neoral in stable pediatric liver transplant recipients.

June 1999, Transplantation proceedings,

R A Superina, and D K Strong, and L A Acal, and E DeLuca

Estimation of mean relative bioavailability of cyclosporine Sandimmune and Neoral using NONMEM in renal transplant recipients.

November 1998, Transplantation proceedings,

R A Superina, and D K Strong, and L A Acal, and E DeLuca

Comparison of pharmacokinetics of Neoral and Sandimmune in stable pediatric liver transplant recipients.

March 1999, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society,

R A Superina, and D K Strong, and L A Acal, and E DeLuca

Comparative bioavailability of Neoral and Sandimmune in cardiac transplant recipients over 1 year.

August 1998, Transplantation proceedings,

R A Superina, and D K Strong, and L A Acal, and E DeLuca

Conversion from Sandimmune to Neoral in stable liver graft recipients.

August 1996, Transplantation proceedings,

R A Superina, and D K Strong, and L A Acal, and E DeLuca

Experience with neoral versus sandimmune in primary liver transplant recipients.

January 1998, Transplant international : official journal of the European Society for Organ Transplantation,

R A Superina, and D K Strong, and L A Acal, and E DeLuca

Conversion from Sandimmune to Neoral and induction therapy with Neoral in pediatric renal transplant recipients.

August 1996, Transplantation proceedings,